OTO open · 2026
Pooled Analysis of Sleep Outcomes After Treatment With Temperature-Controlled Radiofrequency in Nasal Airway Obstruction Patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Takashima Masayoshi, Ananth Ashwin, Hoff Paul T, Lepe Paul Schalch, Setzen Gavin, Suurna Maria V
Аннотация
OBJECTIVE: To assess the long-term impact of temperature-controlled radiofrequency (TCRF) treatment on sleep-related symptoms in patients with nasal airway obstruction (NAO), including those with documented obstructive sleep apnea (OSA).
STUDY DESIGN: Pooled analysis of prospective multicenter studies.
SETTING: Seven academic and 25 private otolaryngology sites.
METHODS: A pooled analysis of 345 adults across four prospective multicenter studies (PIVOTAL, VATRAC, SWELL, and AERWAY) from 7 academic and 25 private otolaryngology sites was conducted. Participants had severe-to-extreme NAO and received a single, office-based TCRF treatment targeting the nasal valve or septal swell body (SSB). Outcomes included sleep-related components of the Nasal Obstruction Symptom Evaluation (NOSE) scale, 22-item Sino-Nasal Outcome Test (SNOT-22) sleep domain, and Epworth Sleepiness Scale (ESS). Analyses included stratification by the presence or absence of OSA and linear regression.
RESULTS: TCRF treatment was associated with significant, durable improvements in sleep-related symptoms through 24 months. At 24 months, the "Trouble Sleeping" subcomponent of the NOSE score improved by -1.9 (95% CI, -2.0 to -1.7) points, a 64% improvement. SNOT-22 sleep domain scores declined by -9.0 (95% CI, -10.5 to -7.6) points, with more than 80% of participants achieving clinical improvement. Among those with excessive daytime sleepiness (ESS ≥ 10), ESS dropped by -8.3 (95% CI, -9.7 to -6.9), and the prevalence of sleepiness fell from 53.8% to 9.8%. Improvements were consistent across the OSA+ subgroup.
CONCLUSION: Office-based TCRF therapy targeting the nasal valve and/or SSB is associated with clinically meaningful, durable improvements in sleep-related symptoms and daytime somnolence in NAO patients, including a subset of those with documented OSA.
STUDY DESIGN: Pooled analysis of prospective multicenter studies.
SETTING: Seven academic and 25 private otolaryngology sites.
METHODS: A pooled analysis of 345 adults across four prospective multicenter studies (PIVOTAL, VATRAC, SWELL, and AERWAY) from 7 academic and 25 private otolaryngology sites was conducted. Participants had severe-to-extreme NAO and received a single, office-based TCRF treatment targeting the nasal valve or septal swell body (SSB). Outcomes included sleep-related components of the Nasal Obstruction Symptom Evaluation (NOSE) scale, 22-item Sino-Nasal Outcome Test (SNOT-22) sleep domain, and Epworth Sleepiness Scale (ESS). Analyses included stratification by the presence or absence of OSA and linear regression.
RESULTS: TCRF treatment was associated with significant, durable improvements in sleep-related symptoms through 24 months. At 24 months, the "Trouble Sleeping" subcomponent of the NOSE score improved by -1.9 (95% CI, -2.0 to -1.7) points, a 64% improvement. SNOT-22 sleep domain scores declined by -9.0 (95% CI, -10.5 to -7.6) points, with more than 80% of participants achieving clinical improvement. Among those with excessive daytime sleepiness (ESS ≥ 10), ESS dropped by -8.3 (95% CI, -9.7 to -6.9), and the prevalence of sleepiness fell from 53.8% to 9.8%. Improvements were consistent across the OSA+ subgroup.
CONCLUSION: Office-based TCRF therapy targeting the nasal valve and/or SSB is associated with clinically meaningful, durable improvements in sleep-related symptoms and daytime somnolence in NAO patients, including a subset of those with documented OSA.